secwatch.observer — SEC 8-K summary
======================================

Issuer:     Olema Pharmaceuticals, Inc. (OLMA)
CIK:        0001750284
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0000950170-24-060031
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Olema reports interim Phase 1b/2 data: palazestrant + ribociclib shows 85% CBR in ER+/HER2- mBC
--------------------------------------------------------------------------------

- Combination well tolerated in 50 patients; no new safety signals and no clinically meaningful drug-drug interaction.
- Clinical benefit rate of 85% (11/13) overall; 83% in ESR1-mutant, 86% in wild-type, 83% in prior CDK4/6i patients.
- Partial responses observed in 5 of 23 evaluable patients (2 confirmed, 3 unconfirmed); 66% remain on treatment.
- Study fully enrolled at 60 patients; data support continued development for first-line ER+/HER2- advanced breast cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750284/000095017024060031/0000950170-24-060031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750284/000095017024060031/olma-20240515.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-060031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer